Paladin Labs Inc. (“Paladin”)(TSX: PLB) and Labopharm Inc. (“Labopharm”)(TSX: DDS) today announced that at the Special Meeting of Labopharm shareholders (the “Meeting”) held today, Labopharm shareholders voted to pass the special resolution (the “Arrangement Resolution”) approving a plan of arrangement by which Chimigen Inc., a wholly-owned subsidiary of Paladin, will acquire all of the issued and outstanding common shares of Labopharm (the “Arrangement”) at a price of $0.2857 per share in cash. 73.24% of the shares voted at the Meeting were cast in favour of the Arrangement Resolution.
